Larkberget

Larkberget AAQS

The The AAQS of Larkberget (LARK.ST) as of Oct 17, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

Larkberget has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Larkberget in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Larkberget AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
3.00 SEK
Jan 1, 2019
3.00 SEK
Jan 1, 2020
3.00 SEK
Jan 1, 2021
3.00 SEK
Jan 1, 2022
3.00 SEK
Jan 1, 2023
3.00 SEK
Jan 1, 2024
3.00 SEK
Jan 1, 2025
3.00 SEK
The Larkberget AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? Larkberget AB, trading under the ticker LARK.ST, is a biotechnology company based in Lidingoe, Sweden. The company, which is listed on the Stockholm Stock Exchange, went public through an IPO on May 25, 2015. Larkberget AB operates within the health care sector, specifically in the biotechnology industry. The company's website is https://combigene.com/. According to the provided information, Larkberget AB is engaged in the development of new treatments for neurological diseases. The firm's platform involves the use of gene therapy vectors to deliver combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. These vectors are designed for the treatment of neurological and psychiatric diseases in both humans and animals. The company focuses on developing an epilepsy treatment using an adeno-associated virus (AAV) vector that carries transgenes for the neurotransmitter NPY and its receptor, the G protein-coupled receptor Y2. The company's headquarters are located in Lidingoe, near Stockholm. Larkberget is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Larkberget stock

The AAQS of Larkberget is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Larkberget since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Larkberget

All Key Metrics — Larkberget